Editorial: Lurbinectedin for neuroendocrine tumors
A new editorial paper was published in Oncoscience, titled "Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer."
Oct 6, 2023
0
47
A new editorial paper was published in Oncoscience, titled "Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer."
Oct 6, 2023
0
47
Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study that assessed ctDNA in the blood of patients with BRAF wild-type (BRAF WT) stage III and IV ...
Oct 4, 2023
0
23
A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has spread beyond the lungs are most likely to benefit from targeted, high-dose radiation, rather than drug-based therapy, ...
Oct 2, 2023
0
19
Researchers at Baylor College of Medicine have developed a new compound called d16 that can reduce tumor growth and overcome therapeutic resistance in mutant p53-bearing cancers in the lab. The findings, published in the ...
Sep 27, 2023
0
9
Northwestern Medicine investigators have discovered how the protein PD-1 controls essential metabolic processes in tumor cells to promote cancer growth in T-cell non-Hodgkin lymphomas (T-NHLs), according to a study published ...
Sep 21, 2023
0
26
The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage ...
Sep 11, 2023
0
1
The Alliance for Clinical Trials in Oncology today announced that an independent Data and Safety Monitoring Board (DSMB) determined that the phase III CABINET (A021602) pivotal trial met its primary endpoint at an interim ...
Aug 24, 2023
0
19
Anti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor therapies, they halt tumor progression in mice models.
Aug 21, 2023
0
49
While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in ...
Jul 13, 2023
0
16
The vast majority of cancer cells have too few or too many copies of some chromosomes, a state known as aneuploidy. But for decades, researchers have debated whether aneuploidy promotes the growth of cancers, or is simply ...
Jun 29, 2023
0
56